GE-04 MGMT METHYLATION IS A POSITIVE PROGNOSTIC MARKER IN PATIENTS WITH ANAPLASTIC ASTROCYTOMA TREATED WITH CONCURRENT TEMOZOLOMIDE AND RADIATION

BACKGROUND: Concurrent radiation (RT) and temozolomide (TMZ) has been accepted as standard first-line therapy for glioblastoma since publication of results of the phase III EORTC/NCIC trial in 2005. In the same NEJM issue, data were presented which showed the prognostic significance of MGMT methylat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Blumenthal, Deborah, Bokstein, Felix, Zelikovitsh, Bracha, Mordechai, Anat, Lossos, Alexander, Taliansky, Alisa, Zach, Lior, Tzuk-Shina, Tzahallah, Lavon, Iris
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218206/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou256.4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items